Platelet secretory mechanisms
- PMID: 15354265
- DOI: 10.1055/s-2004-833479
Platelet secretory mechanisms
Abstract
Platelet granule secretion or exocytosis is required for normal platelet function and plays an important role in the pathogenesis of cardiovascular diseases. Platelets secrete molecules that amplify thrombosis, induce vascular remodeling, recruit and activate cells. The platelet secretory process begins in megakaryocytes where molecules are targeted to developing granules through specific vesicle trafficking and transporter mechanisms. Secretory granules may continue to mature in the circulation after the platelet has been released from the megakaryocyte. The platelet secretory process culminates when ligands interact with specific platelet receptors to trigger exocytosis. A convergence of new insights from several different organisms has begun to illuminate the molecular mechanisms responsible for the platelet secretory process, from granule development through membrane fusion and exocytosis.
Similar articles
-
The exocytosis of human blood platelets. A fast freezing and freeze-substitution analysis.Eur J Cell Biol. 1987 Apr;43(2):273-82. Eur J Cell Biol. 1987. PMID: 3595636
-
The platelet release reaction: granules' constituents, secretion and functions.Platelets. 2001 Aug;12(5):261-73. doi: 10.1080/09537100120068170. Platelets. 2001. PMID: 11487378 Review.
-
Molecular basis of platelet granule secretion.Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1152-60. doi: 10.1161/01.ATV.0000075965.88456.48. Epub 2003 May 8. Arterioscler Thromb Vasc Biol. 2003. PMID: 12738684
-
Regulated granule trafficking in platelets and neurons: a common molecular machinery.Eur J Paediatr Neurol. 2013 Mar;17(2):117-25. doi: 10.1016/j.ejpn.2012.08.005. Epub 2012 Aug 28. Eur J Paediatr Neurol. 2013. PMID: 22951324 Review.
-
The formation of compound granules from different types of secretory organelles in human platelets (dense granules and alpha-granules). A cryofixation/-substitution study using serial sections.Eur J Cell Biol. 1995 Oct;68(2):183-90. Eur J Cell Biol. 1995. PMID: 8575464
Cited by
-
Munc13-4 is a limiting factor in the pathway required for platelet granule release and hemostasis.Blood. 2010 Aug 12;116(6):869-77. doi: 10.1182/blood-2010-02-270934. Epub 2010 Apr 30. Blood. 2010. PMID: 20435885 Free PMC article.
-
No indications for platelet activation in acute clinical myocardial or renal ischemia/reperfusion injury.Am J Transl Res. 2018 Mar 15;10(3):816-826. eCollection 2018. Am J Transl Res. 2018. PMID: 29636871 Free PMC article.
-
Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.Blood. 2007 Mar 1;109(5):1931-7. doi: 10.1182/blood-2006-07-037283. Epub 2006 Nov 2. Blood. 2007. PMID: 17082321 Free PMC article.
-
Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy.Sci Rep. 2017 Jul 18;7(1):5738. doi: 10.1038/s41598-017-05936-3. Sci Rep. 2017. PMID: 28720875 Free PMC article.
-
Platelet aggregation and quality control of platelet concentrates produced in the Amazon Blood Bank.Rev Bras Hematol Hemoter. 2011;33(2):110-4. doi: 10.5581/1516-8484.20110030. Rev Bras Hematol Hemoter. 2011. PMID: 23284257 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources